Proteome-wide Mendelian randomization implicates causal plasma proteins in epilepsy.
1Department of Cardiology, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, Sichuan 610041, China.
Clinical Neurology and Neurosurgery
|March 6, 2026
Summary
This study identified novel protein biomarkers linked to epilepsy risk. Specific proteins like GZMA and TFF1 increase epilepsy risk, while SHBG, CCL15, and ACE may reduce it, offering new diagnostic and therapeutic avenues.
Area of Science:
- Neuroscience
- Genetics
- Biochemistry
Background:
- Epilepsy involves complex molecular alterations.
- Proteomic analysis offers insights into disease mechanisms.
- Identifying biomarkers and therapeutic targets is crucial for epilepsy management.
Purpose of the Study:
- To investigate causal links between plasma protein levels and epilepsy risk.
- To identify novel protein biomarkers for epilepsy and its subtypes.
- To explore pathways involved in epilepsy pathogenesis.
Main Methods:
- Proteome-wide Mendelian randomization meta-analysis.
- Utilized data from large genome-wide association studies.
- Conducted pathway enrichment analysis.
Main Results:
- Identified causal associations between GZMA and TFF1 with increased epilepsy risk.
- Found SHBG, CCL15, and ACE associated with reduced epilepsy risk.
- Discovered specific protein associations with focal and generalized epilepsy subtypes, implicating pathways like regulation of binding and response to electrical stimulus.
Conclusions:
- Identified proteins show potential as biomarkers for early epilepsy diagnosis.
- These proteins may serve as novel therapeutic targets for epilepsy.
- Further experimental validation is needed for clinical translation.
Related Concept Videos
01:24Epilepsy and Seizures: Overview
1.5K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.5K
01:14Antiepileptic Drugs: Glutamate Antagonists
1.1K
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.1K
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
76
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
76